OSBPL2 and colorectal neoplasm: The ERK inhibitor SCH772984 significantly alleviated colorectal tumor growth induced by OSBPL2 knockdown, with reduced average tumor weights and volumes by 41.19% and 39.24%, respectively (Fig. 9B–D).